Our world-class neurology research and development organization is pushing towards novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease.
We view Alzheimer’s disease as an area where we can make a tremendous difference in the lives of patients. Today there are no treatments to prevent, delay or stop the disease progression.
Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide.
This disease destroys not only quality of life but also quantity – it is the 3rd leading cause of mortality in people over 65, behind cancer and heart disease.
Alzheimer’s disease is usually diagnosed in people 65 and older, but it starts earlier with subtle neurological changes occurring years or even decades before symptoms appear. Many people are experiencing the early, often unrecognized, signs of mild cognitive impairment.
Biogen has made a long-term commitment to furthering Alzheimer’s disease research and treatment. Our vision is to redefine Alzheimer’s Disease through innovative medicines to improve the lives of patients and their caregivers.
With an emphasis on early-stage disease, our research programs target several of the identified causes, amyloid and tau pathology – proteins believed to play a critical role in Alzheimer’s disease development. These programs range from preclinical experiments to Phase 3 clinical trials.